103039-34-5

Basic information

• Product Name: 5-methyl-2,4-dinitrobenzoic acid ethyl ester
• Synonyms: 5-methyl-2,4-dinitrobenzoic acid ethyl ester
• CAS NO: 103039-34-5
• Molecular Weight: 254.199
• Mol File: 103039-34-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 5-methyl-2,4-dinitrobenzoic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methyl-2,4-dinitrobenzoic acid ethyl ester(103039-34-5)
• EPA Substance Registry System: 5-methyl-2,4-dinitrobenzoic acid ethyl ester(103039-34-5)

Safety Data

• Hazardous Substances Data: 103039-34-5(Hazardous Substances Data)

Upstream product

• 616-72-8 4,6-dinitro-m-xylene 
• 64-17-5 ethanol 
• 99-04-7 m-Toluic acid 
• 3113-71-1 3-methyl-4-nitrobenzoic acid 
• 3113-72-2 5-methyl-2-nitrobenzoic acid 
• 30650-90-9 3-methyl-4-nitro-benzoic acid ethyl ester 
• 54064-40-3 5-methyl-2-nitrobenzoic acid ethyl ester 
• 99767-48-3 6-methyl-3,5-dinitro-tropolone 
• 1723-15-5 5-methyl-2,4-dinitrobenzoic acid 
• 108-38-3 m-xylene 

Downstream Products

• 873055-32-4 5-(2-dimethylamino-vinyl)-2,4-dinitro-benzoic acid ethyl ester 
• 174311-73-0 (E)-5-<2-(dimethylamino)ethenyl>-2,4-dinitrobenzoic acid ethyl ester 
• 171179-60-5 N-<(dimethylamino)methylene>-(E)-5-<2-(dimethylamino)ethenyl>-2,4-dinitrobenzamide 
• 174311-76-3 (E)-5-<2-(dimethylamino)ethenyl>-2,4-dinitrobenzamide 
• 174311-74-1 6-amino-1H-indole-5-carboxylic acid ethyl ester 
• 27715-62-4 5-methyl-2,4-dinitrobenzamide 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Concise syntheses of the novel 1H-pyrrolo[3,2-g]quinazoline ring system and its [2,3-f] angular isomer

-